Infancy is a critical developmental window during which the gut microbiota and its metabolites contribute to nutrient absorption and overall health. The study reported here sought to evaluate the safety profile and gut microbiota–modulating effects of a specific probiotic strain, Bifidobacterium animalis subsp. lactis CP-9 (CP-9), when administered to otherwise healthy infants. The objective was to determine whether CP-9 supplementation for three months would influence growth, haematological and immunological markers, stool characteristics, and faecal microbiota composition in infants aged 6 to 36 months.
This investigation was conducted as a randomized, double-blind, placebo-controlled trial. Healthy infants between 6 and 36 months of age were randomly assigned to receive either CP-9 or a placebo for a duration of three months. The trial design and blinding were intended to minimize bias when assessing safety, tolerability, growth, and microbiota endpoints. The abstract reports the overarching design and age range; however, specific details such as the number of participants randomized, exact dose and formulation of CP-9, and allocation ratios were not provided in the abstract.
Assessments were performed before and after the intervention period and included measures across multiple domains:
During the three-month intervention, all infants in the trial exhibited age-appropriate growth in both height and head circumference. Haematological parameters and systemic inflammatory markers remained within normal ranges throughout the study period. The authors reported no treatment-related adverse changes in these laboratory or growth measures during the intervention. These observations suggest that, over the trial’s three-month timeframe, CP-9 supplementation did not produce detectable deleterious effects on standard clinical growth or common laboratory safety indicators in this population.
A principal microbiological finding was a significant increase in the abundance of Bifidobacterium among infants receiving CP-9. In addition to taxonomic changes, the study reported modulation of a microbiota-associated metabolic pathway: regulation of the polyunsaturated fatty acids biosynthesis pathway mediated by the gut microbiota. These results indicate that CP-9 supplementation produced measurable alterations in both the composition and inferred metabolic activity of the intestinal microbiota in healthy infants.
CP-9 supplementation was associated with improved stool characteristics and better gastrointestinal tolerability compared with placebo according to the abstract. Importantly, the incidence of clinical events commonly monitored in infant probiotic trials—including respiratory allergies, skin allergies, respiratory infections, and fever—did not increase in the CP-9 group over the three-month period. Collectively, these findings contributed to the assessment that the probiotic did not raise immediate clinical safety concerns in this cohort.
The authors concluded that CP-9 supplementation resulted in significant enrichment of Bifidobacterium, a bacterial group generally regarded as beneficial in infant gut ecosystems, without detectable adverse effects on the measured physiological and clinical parameters. Under the conditions of this trial, CP-9 showed no obvious short-term safety signals in infants aged 6 to 36 months. These outcomes support CP-9 as a probiotic candidate that can modulate gut microbiota composition while appearing safe over a three-month administration period in healthy infants.
The abstract includes a conflict of interest statement, noting involvement of named authors affiliated with a research and development department of a biotech company; the abstract itself is truncated in the provided source and does not list the full conflict text in the excerpt. Additionally, the abstract does not report several methodological and numerical details that are often important for clinical interpretation: specific sample size, exact dosing regimen and formulation of CP-9, randomization numbers per arm, precise statistical results or effect sizes, and detailed counts of adverse events. Those details were not reported in the abstract provided here and would need to be obtained from the full text for a complete appraisal.
In a randomized, double-blind, placebo-controlled trial of healthy infants aged 6–36 months, three months of supplementation with Bifidobacterium animalis subsp. lactis CP-9 significantly increased gut Bifidobacterium abundance, modulated a microbiota-associated polyunsaturated fatty acids biosynthesis pathway, improved stool characteristics and gastrointestinal tolerability, and produced no detectable short-term safety signals in growth, haematology, or measured immunological markers. The abstract reports no rise in respiratory or skin allergies, infections, or fever. For full evaluation of clinical applicability and risk–benefit assessment, the unreported methodological and numerical details in the abstract should be reviewed in the full publication.